Sugiyama T, et al. - Researchers investigated if there was an additional benefit of tirofiban (a glycoprotein IIb/IIIa inhibitor) in patients with plaque erosion presenting with acute coronary syndrome (ACS) who were treated with antiplatelet therapy without stenting. Two groups, tirofiban vs no tirofiban, were identified among patients who completed 1-year follow-up optical coherence tomography imaging in the EROSION study. Similar thrombus volume and marginally greater thrombus burden were detected in the tirofiban group at baseline. The tirofiban group had smaller residual thrombus volume, thrombus burden, and greater reduction of thrombus volume at the 1-month mark, and these differences were sustained up to 1 year. Also in the tirofiban group, complete resolution of thrombus at 1 month was more frequent. An additional benefit of tirofiban on attenuating residual thrombus was seen, without an increased risk for bleeding, among these patients.